Departments of Pharmacology & Regenerative Medicine and Medicine, University of Illinois, Chicago, IL, 60612, USA.
Cell Biochem Biophys. 2021 Sep;79(3):433-444. doi: 10.1007/s12013-021-01002-y. Epub 2021 May 31.
An overview of Prof. Viswanathan Natarajan's journey in academia as a mentor, teacher, and lipid scientist for nearly 50 years is presented. As a graduate student, Dr. Natarajan interrogated biosynthesis and catabolism of phospholipids in the developing brain; however, in the last five decades, he has been investigating the role of sphingolipids and sphingolipid-metabolizing enzymes in pulmonary endothelial cells, epithelial cells, and fibroblasts under normal conditions and during various lung pathologies such as sepsis, asthma, pulmonary hypertension, idiopathic pulmonary fibrosis, bronchopulmonary dysplasia, and lung cancer. His recent work on sphingosine-1-phosphate and lysophosphatidic acid metabolism in pre-clinical animal models has identified small molecule inhibitors in the signaling pathways that could have therapeutic potential in ameliorating pulmonary fibrosis, hypoxia-induced pulmonary hypertension, lung cancer, and bronchopulmonary dysplasia. Future research in bioactive lipids in combination with OMICS should unravel the importance of various lipid mediators as modulators of cell function under normal and pathological conditions.
本文概述了 Viswanathan Natarajan 教授近 50 年来在学术界作为导师、教师和脂质科学家的历程。作为一名研究生,Natarajan 博士研究了磷脂在发育中大脑中的生物合成和分解代谢;然而,在过去的五十年里,他一直在研究鞘脂和鞘脂代谢酶在正常情况下以及在各种肺部疾病(如败血症、哮喘、肺动脉高压、特发性肺纤维化、支气管肺发育不良和肺癌)中的肺内皮细胞、上皮细胞和成纤维细胞中的作用。他最近在临床前动物模型中对神经鞘氨醇-1-磷酸和溶血磷脂酸代谢的研究,确定了信号通路中的小分子抑制剂,这些抑制剂可能在改善特发性肺纤维化、缺氧性肺动脉高压、肺癌和支气管肺发育不良方面具有治疗潜力。生物活性脂质与 OMICS 的结合的未来研究,应该阐明各种脂质介质作为正常和病理条件下细胞功能调节剂的重要性。